Azilsartan
| Title | Journal |
|---|---|
| Azilsartan and its Zn(II) complex. Synthesis, anticancer mechanisms of action and binding to bovine serum albumin. | Toxicology in vitro : an international journal published in association with BIBRA 20180401 |
| Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. | Hypertension research : official journal of the Japanese Society of Hypertension 20140901 |
| Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. | Clinical therapeutics 20140501 |
| Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1. | Chemosphere 20120601 |
| Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. | Hypertension research : official journal of the Japanese Society of Hypertension 20120501 |
| Differential pharmacology and benefit/risk of azilsartan compared to other sartans. | Vascular health and risk management 20120101 |
| Critical evaluation of the efficacy and tolerability of azilsartan. | Vascular health and risk management 20120101 |
| Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. | Vascular health and risk management 20120101 |
| Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. | Diabetes, obesity & metabolism 20111201 |
| Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. | Journal of clinical hypertension (Greenwich, Conn.) 20110701 |
| In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. | The Journal of pharmacology and experimental therapeutics 20110301 |
| Azilsartan: a newly approved angiotensin II receptor blocker. | Cardiology in review 20110101 |
| TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. | American journal of hypertension 20070501 |